Lucy Therapeutics, Inc. — Form D/A
Lucy Therapeutics, Inc. of Waltham, MA, a company, filed a Form D amendment with the SEC on 2020-07-22. The offering totals $4.5M, of which $3.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-07-22
- Form: D/A
- Accession: 0001782250-20-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $4.5M
- Amount sold: $3.0M
- Remaining: $1.5M
- Investors: 4
- Date of first sale: 2019-06-28
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-344266
Issuer
- Name: Lucy Therapeutics, Inc.
- CIK: 0001782250
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 21 Hickory Drive, Suite 2B, Waltham, MA, 02451
- Phone: 617-249-4812
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Ann DeWitt | Director | Woburn, MA |
| Rachel Sha | Director | Woburn, MA |
| Robert Michael Poole | Director | Waltham, MA |
| Amy Ripka | Director | Waltham, MA |
| Amy Ripka | Executive Officer | Waltham, MA |
| John Ripple | Director | Waltham, MA |
| Karoly Nikolich | Director | Cambridge, MA |
Other filings by this issuer (4)
More